Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-11-2024 | Lung Cancer | Review

Opportunities and challenges of using circulating tumor DNA to predict lung cancer immunotherapy efficacy

Authors: Shanshan Li, Ting Yuan, Jing Yuan, Bo Zhu, Degao Chen

Published in: Journal of Cancer Research and Clinical Oncology | Issue 11/2024

Abstract

Immune checkpoint inhibitors (ICIs), particularly anti-programmed death 1 (PD-1)/ programmed death ligand 1 (PD-L1) antibodies, have led to significant progress in lung cancer treatment. However, only a minority of patients have responses to these therapies. Detecting peripheral blood of circulating tumor DNA (ctDNA) allows minimally invasive diagnosis, characterization, and monitoring of lung cancer. ctDNA has potential to be a prognostic biomarker and a predictor of the response to ICI therapy since it can indicate the genomic status and tumor burden. Recent studies on lung cancer have shown that pretreatment ctDNA analysis can detect residual proliferative disease in the adjuvant immunotherapy setting and evaluate tumor burden in patients with metastatic disease. Early ctDNA dynamics can not only predict the clinical outcome of ICI therapy but also help distinguish between pseudoprogression and real progression. Furthermore, in addition to quantitative assessment, ctDNA can also detect genetic predictors of response to ICI therapy. However, barriers still exist in the application of ctDNA analysis in clinical lung cancer treatment. The predictive value of ctDNA in lung cancer immunotherapy requires further identification and resolution of these challenges. This review aims to summarize the existing data of ctDNA analysis in patients receiving immunotherapy for lung cancer, understand the limitations of clinical treatment, and discuss future research directions.

Abbosh C, Birkbak NJ, Wilson GA et al (2017) Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature 545:446–451. https://doi.org/10.1038/nature22364CrossRefPubMedPubMedCentral

Abbosh C, Birkbak NJ, Swanton C (2018) Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol 15:577–586. https://doi.org/10.1038/s41571-018-0058-3CrossRefPubMed

Aggarwal C, Thompson JC, Chien AL et al (2020) Baseline plasma Tumor Mutation Burden predicts response to Pembrolizumab-based Therapy in patients with Metastatic non–small cell Lung Cancer. Clin Cancer Res 26:2354–2361. https://doi.org/10.1158/1078-0432.CCR-19-3663CrossRefPubMedPubMedCentral

Anagnostou V, Forde PM, White JR et al (2019) Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Res 79:1214–1225. https://doi.org/10.1158/0008-5472.CAN-18-1127CrossRefPubMed

Anagnostou V, Niknafs N, Marrone K et al (2020) Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nat Cancer 1:99–111. https://doi.org/10.1038/s43018-019-0008-8CrossRefPubMedPubMedCentral

Anagnostou V, Landon BV, Medina JE et al (2022) Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. Sci Transl Med 14:eabo3958. https://doi.org/10.1126/scitranslmed.abo3958CrossRefPubMedPubMedCentral

Assaf ZJF, Zou W, Fine AD et al (2023) A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat Med 29:859–868. https://doi.org/10.1038/s41591-023-02226-6CrossRefPubMedPubMedCentral

AstraZeneca (2019) Update on the Phase III NEPTUNE trial of Imfinzi plus Tremelimumab in Stage IV nonsmall cell lung cancer

Avanzini S, Kurtz DM, Chabon JJ et al (2020) A mathematical model of ctDNA shedd-ing predicts tumor detection size. Sci Adv 6:eabc4308. https://doi.org/10.1126/sciadv.abc4308CrossRefPubMedPubMedCentral

Berti A, Bortolotti R, Dipasquale M et al (2021) Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer. Crit Rev Oncol/Hematol 162:103351. https://doi.org/10.1016/j.critrevonc.2021.103351CrossRefPubMed

Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus Docetaxel in Advanced non-squamous non-small cell Lung Cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643CrossRefPubMedPubMedCentral

Bratman SV, Yang SYC, Iafolla MAJ et al (2020) Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer 1:873–881. https://doi.org/10.1038/s43018-020-0096-5CrossRefPubMed

Cabel L, Riva F, Servois V et al (2017) Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Ann Oncol 28:1996–2001. https://doi.org/10.1093/annonc/mdx212CrossRefPubMed

Cabel L, Proudhon C, Romano E et al (2018) Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nat Rev Clin Oncol 15:639–650. https://doi.org/10.1038/s41571-018-0074-3CrossRefPubMed

Carbone DP, Reck M, Paz-Ares L et al (2017) First-line nivolumab in stage IV or recurrent non-small-cell Lung Cancer. N Engl J Med 376:2415–2426. https://doi.org/10.1056/NEJMoa1613493CrossRefPubMedPubMedCentral

Chaffer CL, Weinberg RA (2011) A perspective on Cancer Cell Metastasis. Science 331:1559–1564. https://doi.org/10.1126/science.1203543CrossRefPubMed

Chaudhuri AA, Chabon JJ, Lovejoy AF et al (2017) Early detection of molecular residual disease in localized Lung Cancer by circulating Tumor DNA profiling. Cancer Discov 7:1394–1403. https://doi.org/10.1158/2159-8290.CD-17-0716CrossRefPubMedPubMedCentral

Chiou VL, Burotto M (2015) Pseudoprogression and Immune-related response in So-lid tumors. J Clin Oncol 33:3541–3543. https://doi.org/10.1200/JCO.2015.61.6870CrossRefPubMedPubMedCentral

Cristiano S, Leal A, Phallen J et al (2019) Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570:385–389. https://doi.org/10.1038/s41586-019-1272-6CrossRefPubMedPubMedCentral

De Castro G, Rizvi NA, Schmid P et al (2023) NEPTUNE: phase 3 study of First-Line Durvalumab Plus Tremelimumab in patients with metastatic NSCLC. J Thorac Oncol 18:106–119. https://doi.org/10.1016/j.jtho.2022.09.223CrossRefPubMed

Diehl F, Schmidt K, Choti MA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985–990. https://doi.org/10.1038/nm.1789CrossRefPubMed

Dong ZY, Zhong WZ, Zhang XC et al (2017) Potential predictive value of TP53 and KRAS Mutation Status for response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res 23:3012–3024. https://doi.org/10.1158/1078-0432.CCR-16-2554CrossRefPubMed

Duffy MJ, Crown J (2019) Biomarkers for Predicting Response to Immunotherapy with Immune checkpoint inhibitors in Cancer patients. Clin Chem 65:1228–1238. https://doi.org/10.1373/clinchem.2019.303644CrossRefPubMed

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME et al (2018) Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respiratory Med 6:771–781. https://doi.org/10.1016/S2213-2600(18)30284-4CrossRef

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026CrossRefPubMed

Felip E, Altorki N, Zhou C et al (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398:1344–1357. https://doi.org/10.1016/S0140-6736(21)02098-5CrossRefPubMed

Ferrara R, Caramella C, Besse B, Champiat S (2019) Pseudoprogression in non–small cell Lung Cancer upon Immunotherapy: few drops in the Ocean? J Thorac Oncol 14:328–331. https://doi.org/10.1016/j.jtho.2018.12.011CrossRefPubMed

Frelaut M, Du Rusquec P, De Moura A et al (2020) Pseudoprogression and Hyperprogression as New forms of response to Immunotherapy. BioDrugs 34:463–476. https://doi.org/10.1007/s40259-020-00425-yCrossRefPubMed

Fricke J, Mambetsariev I, Pharaon R et al (2020) Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11. Med (Baltim) 99:e22323. https://doi.org/10.1097/MD.0000000000022323CrossRef

Gandara DR, Paul SM, Kowanetz M et al (2018) Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med 24:1441–1448. https://doi.org/10.1038/s41591-018-0134-3CrossRefPubMed

Gandhi L, Rodríguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus Chemotherapy in Metastatic non–small-cell Lung Cancer. N Engl J Med 378:2078–2092. https://doi.org/10.1056/NEJMoa1801005CrossRefPubMed

Garassino MC, Cho B-C, Kim J-H et al (2018) Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, singl-e-arm, phase 2 study. Lancet Oncol 19:521–536. https://doi.org/10.1016/S1470-2045(18)30144-XCrossRefPubMedPubMedCentral

Garofalo A, Sholl L, Reardon B et al (2016) The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med 8:79. https://doi.org/10.1186/s13073-016-0333-9CrossRefPubMedPubMedCentral

Giroux Leprieur E, Herbretau G, Dumenil C et al (2018) Circulating tumor DNA evaluated by Next-Generation sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer. OncoImmunology 7:e1424675. https://doi.org/10.1080/2162402X.2018.1424675CrossRefPubMedPubMedCentral

Giroux Leprieur E, Hélias-Rodzewicz Z, Takam Kamga P et al (2020) Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression. J Immunother Cancer 8:e000527. https://doi.org/10.1136/jitc-2020-000527CrossRefPubMedPubMedCentral

Goldberg SB, Narayan A, Kole AJ et al (2018) Early Assessment of Lung Cancer Immunotherapy Response via circulating Tumor DNA. Clin Cancer Res 24:1872–1880. https://doi.org/10.1158/1078-0432.CCR-17-1341CrossRefPubMedPubMedCentral

Goldman JW, Dvorkin M, Chen Y et al (2021) Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 22:51–65. https://doi.org/10.1016/S1470-2045(20)30539-8CrossRefPubMed

Guibert N, Mazieres J, Delaunay M et al (2017) Monitoring of KRAS -mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 trea-tment of lung adenocarcinoma. Oncotarget 8:38056–38060. https://doi.org/10.18632/oncotarget.16935CrossRefPubMedPubMedCentral

Guibert N, Delaunay M, Lusque A et al (2018) PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer 120:108–112. https://doi.org/10.1016/j.lungcan.2018.04.001CrossRefPubMed

Guibert N, Jones G, Beeler JF et al (2019) Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Lung Cancer 137:1–6. https://doi.org/10.1016/j.lungcan.2019.09.005CrossRefPubMed

Gupta GP, Massagué J (2006) Cancer Metastasis: building a Framework. Cell 127:679–695. https://doi.org/10.1016/j.cell.2006.11.001CrossRefPubMed

Han X, Tang X, Zhu H et al (2022) Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial. J Immunother Cancer 10:e004952. https://doi.org/10.1136/jitc-2022-004952CrossRefPubMedPubMedCentral

Hellmann MD, Paz-Ares L, Bernabe Caro R et al (2019) Nivolumab plus Ipilimumab in Advanced non–small-cell Lung Cancer. N Engl J Med 381:2020–2031. https://doi.org/10.1056/NEJMoa1910231CrossRefPubMed

Hellmann MD, Nabet BY, Rizvi H et al (2020) Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC. Clin Cancer Res 26:2849–2858. https://doi.org/10.1158/1078-0432.CCR-19-3418CrossRefPubMedPubMedCentral

Herbreteau G, Langlais A, Greillier L et al (2020) Circulating tumor DNA as a prognostic determinant in small cell Lung Cancer patients receiving atezolizumab. J Clin Med 9:3861. https://doi.org/10.3390/jcm9123861CrossRefPubMedPubMedCentral

Hirsch FR, McElhinny A, Stanforth D et al (2017) PD-L1 immunohistochemistry assays for Lung Cancer: results from phase 1 of the blueprint PD-L1 IHC assay co-mparison project. J Thorac Oncol 12:208–222. https://doi.org/10.1016/j.jtho.2016.11.2228CrossRefPubMed

Ignatiadis M, Sledge GW, Jeffrey SS (2021) Liquid biopsy enters the clinic — implementation issues and future challenges. Nat Rev Clin Oncol 18:297–312. https://doi.org/10.1038/s41571-020-00457-xCrossRefPubMed

Janning M, Kobus F, Babayan A et al (2019) Determination of PD-L1 expression in circulating Tumor cells of NSCLC patients and correlation with response to PD-1/PD-L1 inhibitors. Cancers 11:835. https://doi.org/10.3390/cancers11060835CrossRefPubMedPubMedCentral

Jensen TJ, Goodman AM, Kato S et al (2019) Genome-wide sequencing of cell-free DNA identifies Copy-number alterations that can be used for monitoring response to Immunotherapy in Cancer patients. Mol Cancer Ther 18:448–458. https://doi.org/10.1158/1535-7163.MCT-18-0535CrossRefPubMed

Jia Q, Wang J, He N et al (2019) Titin mutation associated with responsiveness to Che-Ckpoint blockades in solid tumors. JCI Insight 4:e127901. https://doi.org/10.1172/jci.insight.127901CrossRefPubMedPubMedCentral

Jia Q, Chiu L, Wu S et al (2020) Tracking neoantigens by Personalized circulating tumor DNA sequencing during checkpoint blockade immunotherapy in Non-sm-all Cell Lung Cancer. Adv Sci 7:1903410. https://doi.org/10.1002/advs.201903410CrossRef

Keller L, Belloum Y, Wikman H, Pantel K (2021) Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer 124:345–358. https://doi.org/10.1038/s41416-020-01047-5CrossRefPubMed

Kim ES, Velcheti V, Mekhail T et al (2022) Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nat Med 28:939–945. https://doi.org/10.1038/s41591-022-01754-xCrossRefPubMedPubMedCentral

Koeppel F, Blanchard S, Jovelet C et al (2017) Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS ONE 12:e0188174. https://doi.org/10.1371/journal.pone.0188174CrossRefPubMedPubMedCentral

Koyama S, Akbay EA, Li YY et al (2016) STK11/LKB1 Deficiency promotes Neutrophil Recruitment and Proinflammatory Cytokine production to suppress T-cell activity in the lung Tumor Microenvironment. Cancer Res 76:999–1008. https://doi.org/10.1158/0008-5472CrossRefPubMedPubMedCentral

Li L, Wang Y, Shi W et al (2019) Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non‐small cell lung cancer patients treated wit-h anti‐PD1 immunotherapy. Cancer Med 8:7669–7678. https://doi.org/10.1002/cam4.2632CrossRefPubMedPubMedCentral

Liu Y, Dong Z, Jiang T et al (2018) Heterogeneity of PD-L1 expression among the different histological components and metastatic lymph nodes in patients with resected lung adenosquamous carcinoma. Clin Lung Cancer 19:e421–e430. https://doi.org/10.1016/j.cllc.2018.02.008CrossRefPubMed

Liu SV, Reck M, Mansfield AS et al (2021) Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung Cancer treated with atezolizumab, carboplatin, and Etoposide (IMpower133). J Clin Oncol 39:619–630. https://doi.org/10.1200/JCO.20.01055CrossRefPubMedPubMedCentral

Mansfield AS, Aubry MC, Moser JC et al (2016) Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol 27:1953–1958. https://doi.org/10.1093/annonc/mdw289CrossRefPubMedPubMedCentral

Marinelli D (2020) KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Ann Oncol 31:1746–1754. https://doi.org/10.1016/j.annonc.2020.08.2105CrossRefPubMed

McGranahan N, Furness AJS, Rosenthal R et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:1463–1469. https://doi.org/10.1126/science.aaf1490CrossRefPubMedPubMedCentral

Moding EJ, Liu Y, Nabet BY et al (2020) Circulating Tumor DNA Dynamics Predict Benefit from consolidation immunotherapy in locally Advanced Non-small Cell Lung Cancer. Nat Cancer 1:176–183. https://doi.org/10.1038/s43018-019-0011-0CrossRefPubMedPubMedCentral

Munari E, Zamboni G, Lunardi G et al (2018) PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and cl-one SP263. Oncotarget 9:30465–30471. https://doi.org/10.18632/oncotarget.25770CrossRefPubMedPubMedCentral

Nabet BY, Esfahani MS, Moding EJ et al (2020) Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell 183:363–376e13. https://doi.org/10.1016/j.cell.2020.09.001CrossRefPubMedPubMedCentral

O’Brien M, Paz-Ares L, Marreaud S et al (2022) Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 23:1274–1286. https://doi.org/10.1016/S1470-2045(22)00518-6CrossRefPubMed

Peng W, Chen JQ, Liu C et al (2016) Loss of PTEN promotes resistance to T Cell-M-ediated immunotherapy. Cancer Discov 6:202–216. https://doi.org/10.1158/2159-8290.CD-15-0283CrossRefPubMed

Peters S, Spigel D, Ahn M et al (2021) P03.03 MERMAID-1: a phase III study of Ad-juvant Durvalumab plus Chemotherapy in Resected NSCLC patients with MRD + post-surgery. J Thorac Oncol 16:S258–S259. https://doi.org/10.1016/j.jtho.2021.01.376CrossRef

Peters S, Dziadziuszko R, Morabito A et al (2022) Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat Med 28:1831–1839. https://doi.org/10.1038/s41591-022-01933-wCrossRefPubMedPubMedCentral

Phallen J, Sausen M, Adleff V et al (2017) Direct detection of early-stage cancers usin-g circulating tumor DNA. Sci Transl Med 9:eaan2415. https://doi.org/10.1126/scitranslmed.aan2415CrossRefPubMedPubMedCentral

Provencio M, Nadal E, Insa A et al (2020) Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, si-ngle-arm, phase 2 trial. Lancet Oncol 21:1413–1422. https://doi.org/10.1016/S1470-2045(20)30453-8CrossRefPubMed

Provencio M, Serna-Blasco R, Nadal E et al (2022) Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA non–small-cell lung Cancer (NADIM phase II trial). J Clin Oncol 40:2924–2933. https://doi.org/10.1200/JCO.21.02660CrossRefPubMedPubMedCentral

Queirolo P, Spagnolo F (2017) Atypical responses in patients with advanced melanom-a, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: a systematic review. Cancer Treat Rev 59:71–78. https://doi.org/10.1016/j.ctrv.2017.07.002CrossRefPubMed

Raja R, Kuziora M, Brohawn PZ et al (2018) Early reduction in ctDNA predicts Surv-Ival in patients with lung and bladder Cancer treated with Durvalumab. Clin Cancer Res 24:6212–6222. https://doi.org/10.1158/1078-0432.CCR-18-0386CrossRefPubMed

Ready N, Hellmann MD, Awad MM et al (2019) First-line Nivolumab Plus Ipilimumab in Advanced non–small-cell Lung Cancer (CheckMate 568): outcomes by programmed death Ligand 1 and Tumor Mutational Burden as biomarkers. J Clin Oncol 37:992–1000. https://doi.org/10.1200/JCO.18.01042CrossRefPubMedPubMedCentral

Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus Chemotherapy for PD-L1–Positive non–small-cell Lung Cancer. N Engl J Med 375:1823–1833. https://doi.org/10.1056/NEJMoa1606774CrossRefPubMed

Reck M, Rodríguez–Abreu D, Robinson AG et al (2019) Updated analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-based chemotherapy for Advanced non–small-cell Lung Cancer with PD-L1 Tumor Proportion score of 50% or Greater. JCO 37:537–546. https://doi.org/10.1200/JCO.18.00149CrossRef

Ren S, Chen J, Xu X et al (2022) Camrelizumab Plus Carboplatin and Paclitaxel as First-Line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 Tria-l. J Thorac Oncol 17:544–557. https://doi.org/10.1016/j.jtho.2021.11.018CrossRefPubMed

Ribas A, Chmielowski B, Glaspy JA (2009) Do we need a different Set of Response Assessment Criteria for Tumor Immunotherapy? Clin Cancer Res 15:7116–7118. https://doi.org/10.1158/1078-0432.CCR-09-2376CrossRefPubMed

Ricciuti B, Jones G, Severgnini M et al (2021) Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). J Immunother Cancer 9:e001504. https://doi.org/10.1136/jitc-2020-001504CrossRefPubMedPubMedCentral

Rizvi H, Sanchez-Vega F, La K et al (2018) Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell Lung Cancer profiled with targe-ted next-generation sequencing. J Clin Oncol 36:633–641. https://doi.org/10.1200/JCO.2017.75.3384CrossRefPubMedPubMedCentral

Rizvi NA, Cho BC, Reinmuth N et al (2020) Durvalumab with or without Tremelimumab vs Standard Chemotherapy in First-line treatment of Metastatic non–small cell Lung Cancer: the MYSTIC Phase 3 Randomized Clinical Trial. JAMA Oncol 6:661. https://doi.org/10.1001/jamaoncol.2020.0237CrossRefPubMedPubMedCentral

Ruppert AM, Beau-Faller M, Debieuvre D et al (2020) Outcomes of patients with Advanced NSCLC from the Intergroupe Francophone De Cancérologie Thoracique biomarkers France Study by KRAS Mutation subtypes. JTO Clin Res Rep 1:100052. https://doi.org/10.1016/j.jtocrr.2020.100052CrossRefPubMedPubMedCentral

Samstein RM, Lee C-H, Shoushtari AN et al (2019) Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51:202–206. https://doi.org/10.1038/s41588-018-0312-8CrossRefPubMedPubMedCentral

Sha D, Jin Z, Budzcies J et al (2020) Tumor Mutational Burden (TMB) as a Predictiv-e biomarker in solid tumors. Cancer Discov 10:1808–1825. https://doi.org/10.1158/2159-8290.CD-20-0522CrossRefPubMedPubMedCentral

Sinoquet L, Jacot W, Quantin X, Alix-Panabières C (2023) Liquid Biopsy and Immuno-Oncology for Advanced Nonsmall Cell Lung Cancer. Clin Chem 69:23–40. https://doi.org/10.1093/clinchem/hvac166CrossRefPubMed

Spigel DR, Peters S, Ahn M-J et al (2021) 93TiP MERMAID-2: phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD + after curative-intent therapy. J Thorac Oncol 16:S745–S746. https://doi.org/10.1016/S1556-0864(21)01935-3CrossRef

Stadler J-C, Belloum Y, Deitert B et al (2022) Current and future clinical Application-s of ctDNA in Immuno-Oncology. Cancer Res 82:349–358. https://doi.org/10.1158/0008-5472.CAN-21-1718CrossRefPubMed

Su C, Wang X, Zhou J et al (2021) Titin mutation in circulatory tumor DNA is associa-ted with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer. Transl Lung Cancer Res 10:1256–1265. https://doi.org/10.21037/tlcr-20-1118CrossRefPubMedPubMedCentral

Sun Y, Duan J, Fang W et al (2021) Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC. BMC Med 19:239. https://doi.org/10.1186/s12916-021-02075-5CrossRefPubMedPubMedCentral

Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 Countrie-s. CA: a Cancer. J Clin 71:209–249. https://doi.org/10.3322/caac.21660CrossRef

Tazdait M, Mezquita L, Lahmar J et al (2018) Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer 88:38–47. https://doi.org/10.1016/j.ejca.2017.10.017CrossRefPubMed

Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275–287. https://doi.org/10.1038/nrc.2016.36CrossRefPubMedPubMedCentral

van der Leest P, Hiddinga B, Miedema A et al (2021) Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors. Mol Oncol 15:2910–2922. https://doi.org/10.1002/1878-0261.13090CrossRefPubMedPubMedCentral

Wang Z, Duan J, Wang G et al (2020) Allele frequency–adjusted blood-based Tumor Mutational Burden as a predictor of overall survival for patients with NSCLC treated with PD-(L)1 inhibitors. J Thorac Oncol 15:556–567. https://doi.org/10.1016/j.jtho.2019.12.001CrossRefPubMed

Weiss GJ, Beck J, Braun DP et al (2017) Tumor cell–free DNA Copy Number Instability predicts therapeutic response to Immunotherapy. Clin Cancer Res 23:5074–5081. https://doi.org/10.1158/1078-0432.CCR-17-0231CrossRefPubMed

Wolchok JD, Hoos A, O’Day S et al (2009) Guidelines for the evaluation of Immune Therapy activity in solid tumors: Immune-Related Response Criteria. Clin Cancer Res 15:7412–7420. https://doi.org/10.1158/1078-0432.CCR-09-1624CrossRefPubMed

Yamauchi T, Hoki T, Oba T et al (2021) T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nat Commun 12:1402. https://doi.org/10.1038/s41467-021-21619-0CrossRefPubMedPubMedCentral

Yang N, Li Y, Liu Z et al (2018) The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues. BMC Cancer 18:319. https://doi.org/10.1186/s12885-018-4199-7CrossRefPubMedPubMedCentral

Zhang Q, Luo J, Wu S et al (2020) Prognostic and predictive impact of circulating Tumor DNA in patients with Advanced Cancers treated with Immune Checkpoint Blockade. Cancer Discov 10:1842–1853. https://doi.org/10.1158/2159-8290.CD-20-0047CrossRefPubMedPubMedCentral

Zou W, Yaung SJ, Fuhlbrück F et al (2021) ctDNA predicts overall survival in patients with NSCLC treated with PD-L1 blockade or with chemotherapy. JCO Precision Oncol 5:827–838. https://doi.org/10.1200/PO.21.00057CrossRef

Title: Opportunities and challenges of using circulating tumor DNA to predict lung cancer immunotherapy efficacy
Authors: Shanshan Li
Ting Yuan
Jing Yuan
Bo Zhu
Degao Chen
Publication date: 01-11-2024
Publisher: Springer Berlin Heidelberg
Keywords: Lung Cancer
Checkpoint Inhibitors
Molecular Genetics
Lung Cancer
Published in: Journal of Cancer Research and Clinical Oncology / Issue 11/2024
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-024-06030-8

Five-year overall survival of early- and late-onset colorectal cancer in Medellín, Colombia: a comparative study

Open Access
Research

Effects of preoperative neoadjuvant chemotherapy on postoperative delirium in patients with gynecological tumor surgery: an observational study

Open Access
Research

Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability

Open Access
Research

Oncological junior groups across medical specialties in Germany join forces and launch an interdisciplinary alliance: Young Oncologists United (YOU)

Open Access
Correspondence

A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockade

Open Access
Research

Insights into cancer characteristics among SARS-CoV-2 infected hospitalized patients: a comprehensive analysis from the National Clinical Registry for COVID-19

Open Access
Research

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Targeted Therapy
On-demand webinar

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Keynote series | Spotlight on menopause

Springer Medicine

Opportunities and challenges of using circulating tumor DNA to predict lung cancer immunotherapy efficacy

Abstract

Other articles of this Issue 11/2024

Five-year overall survival of early- and late-onset colorectal cancer in Medellín, Colombia: a comparative study

Effects of preoperative neoadjuvant chemotherapy on postoperative delirium in patients with gynecological tumor surgery: an observational study

Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability

Oncological junior groups across medical specialties in Germany join forces and launch an interdisciplinary alliance: Young Oncologists United (YOU)

A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockade

Insights into cancer characteristics among SARS-CoV-2 infected hospitalized patients: a comprehensive analysis from the National Clinical Registry for COVID-19

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Please log in to get access to this content